Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treprostinil - United Therapeutics Corporation

Drug Profile

Treprostinil - United Therapeutics Corporation

Alternative Names: 15AU; 15AU81; ARD-1500; ARD-1550; BW 15AU; BW 15AU81; BW A15AU; LRX 15; MD 711; MD-0701; OreniCell; OreniLeft; Orenitram; Remodulin; Sustained-release treprostinil - United Therapeutics; TransCon treprostinil; Treprost; Treprostenol; Treprostinil diolamine; Treprostinol; Tresprostinol diethanolamine; Tyvaso; U 62840; Uniprost; UT 15; UT-15C; UT-15C SR

Latest Information Update: 04 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline; Pfizer
  • Developer Ascendis Pharma; Ferrer; Lees Pharmaceutical Holdings; Mochida Pharmaceutical; United Therapeutics Corporation
  • Class Antihypertensives; Prostaglandins; Skin disorder therapies; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension
  • Phase II Systemic scleroderma
  • Discontinued Cancer; Heart failure; Peripheral ischaemia

Most Recent Events

  • 31 Jan 2019 Additional efficacy data from the phase III FREEDOM-EV trial in pulmonary arterial hypertension released by United Therapeutics
  • 14 Jan 2019 Ascendis Pharma terminates a phase I trial in Healthy volunteers due to local tolerance expectations not being met (SC, Injection) (NCT03803163)
  • 21 Dec 2018 Lung Biotechnology in collaboration with United Therapeutics initiates enrolment in the PERFECTOLE trial for Pulmonary arterial hypertension in USA (Inhalation) (NCT03794583)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top